In a small Phase 1b study of six relapsed/refractory multiple myeloma patients, continuous low‑dose lenalidomide (STAR-LLD) produced one complete response and five partial responses, with no drug-related hematologic toxicities above grade 2 across up to 12 treatment cycles. Those early signals now underpin a randomized Phase 2a program designed to test whether continuous subcutaneous delivery can sustain efficacy while reducing the hematologic burden seen with standard oral dosing.
Starton has dosed the first patient in its Phase 2a trial comparing three doses of STAR-LLD, administered by continuous subcutaneous infusion, against a daily 25 mg oral lenalidomide regimen. Both arms include dexamethasone and a proteasome inhibitor. The study plans to enroll 24 transplant-ineligible patients in second line or later, with an option to expand to 69 based on the recommended Phase 2 dose and response rate. Enrollment completion is targeted for the first half of 2027. Operationally, the company is scaling from two to six U.S. sites through the Sargon Site Network, broadening geographic reach as it moves into a dose-finding randomized design.
Strategically, this is an attempt to reframe an entrenched backbone therapy through pharmacokinetic engineering rather than new mechanism. If continuous infusion can flatten peaks and maintain a minimum effective exposure, the approach could mitigate cytopenias that drive dose interruptions and discontinuations on oral lenalidomide. That thesis will be tested directly against a widely used reference regimen at a time when oral lenalidomide is generic and deeply embedded in treatment pathways. A credible tolerability and adherence advantage could create room for a premium, particularly in older, transplant‑ineligible populations who often struggle to stay on therapy, but the bar for displacement is high given the cost differential and the availability of next‑generation agents.
For sites and CROs, the protocol introduces distinct operational considerations versus oral IMiDs. Continuous subcutaneous infusion will require device management, training on insertion and troubleshooting, documentation of local site reactions, and coordination for at‑home versus in‑clinic support. Workflows must also align with lenalidomide’s existing REMS framework, adding a layer of compliance to device oversight. The network-based expansion to six centers should help mitigate single‑site bottlenecks, but the projected timeline through 2027 suggests recruitment and logistics will need tight management in a crowded myeloma landscape where bispecifics, CAR-T, and CELMoDs are competing for similar patient pools.
Regulatory strategy likely hinges on a 505(b)(2) pathway leveraging lenalidomide’s established efficacy while demonstrating that continuous delivery achieves comparable or superior outcomes with improved tolerability. As a combination product, STAR-LLD will have to clear device reliability, manufacturing, and human factors expectations alongside clinical endpoints. From a payer perspective, reduced dose holds, fewer transfusions, and longer time on therapy could frame an economic argument, but those outcomes must be prospectively captured and convincingly tied to exposure modulation rather than background regimen effects.
Near term, watch for the selected dose and early comparative signals on hematologic toxicity, injection‑site events, device performance, and duration on therapy. Consistency across proteasome inhibitor backbones will matter for generalizability. Enrollment velocity across the expanded network will be a leading indicator of operational feasibility. If the Phase 2a readout confirms the Phase 1b tolerability signal with maintained response, a dose‑expansion or streamlined registrational plan could follow; if not, the window narrows as CELMoDs and T‑cell–redirecting modalities continue to move earlier in sequence. The pivotal question is whether delivery innovation alone can reposition a mature class in a field now defined by deeper—but often more toxic—responses.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
